Sannuo三诺品牌怎么样 官方旗舰店

三诺生物传感股份有限公司主营业务是利用生物传感技术研发、生产、销售即时检测产品，在深圳证券交易所挂牌上市，股票简称“三诺生物”，股票代码300298。公司主要产品为微量血快速血糖测试仪及配套血糖检测试条，构成血糖监测系统，用于血糖监测。

三诺生物2003年和2008年两度获得了国家创新基金支持，并且是国家生物医学工程高技术产业化示范项目的承担单位。作为国内最主要的生产血糖监测系统产品的厂商之一，公司生产的“SXT-1型”、“安稳型”、“安准型”血糖测试仪及配套试条均取得医疗器械产品注册证书，公司经湖南省食品药品监督管理局现场审核合格后获得医疗器械生产许可证。此外，公司还通过了ISO:13485质量管理体系认证。在产品出口方面，公司生产的血糖监测系统产品通过了欧盟CE认证。

公司业绩快速增长依赖于独特的盈利模式。公司的主要产品包括血糖测试仪及配套试条，两者必须配对使用。公司即采取了仪器占领市场、耗材赚取利润的盈利模式，通过提供普通老百姓可负担得起的血糖仪及试条来占领市场，仪器售出后带动相应试条呈现累积增长。过去3年仪器销量大幅增长，收入复合增速25%；试条价格保持稳定，过去3年收入复合增速119%。

“生物传感器生产基地”的建成将有效巩固并提高公司在微量血快速血糖测试仪及配套血糖测试试条产品的综合竞争力，提高生产工艺，提升公司产品质量，解决产能不足的问题，全面提升公司在国内血糖监测系统行业的竞争地位。有助于公司巩固国内市场、开拓国际市场、扩大市场份额、提升品牌价值、开发新产品、进一步提高核心竞争力。“营销网络建设”项目能进一步提高公司产品市场覆盖率，提升产品品牌形象，加强公司的客户服务能力，为公司获取更大的市场份额和覆盖更高层次的市场奠定基础。

三诺生物建立了一支国内血糖检测行业至今最大最专业的营销队伍，他们广泛的活跃于全国省市县等各级市场，有计划的进行着各种各样的促销活动、患教活动，促使了三诺系列血糖仪的快速、大量出货，从而带动了与之相匹配的血糖测试条销量的持续快速增长，一大批多年合作的经销商、药店同样获得了可观的销售回报。

近日科技部门公布了《医学科技发展“十二五”规划》，《规划》提出以重大新药、医疗器械、中药现代化为核心，发展生物医药战略性新兴产业。基于生物传感技术的血糖仪企业将受益于政策扶持下的产品市场扩容。预计未来5年中国新增血糖测试仪市场容量为46.82亿元，每年消耗试条容量为81.63亿元，合计达到128.45亿元，巨大的市场容量将为三诺生物的长足发展提供有力保障。

未来，三诺生物将继续致力于POCT（即时检测）产品的研发和产业化，保持公司在血糖监测系统行业的领先地位,引领糖尿病、心血管疾病和传染性疾病POCT产品的规模化和市场化，为急诊、床旁快速检测和慢性疾病管理提供检测工具和信息管理服务，形成监测评估干预的疾病管理物联网交互系统，实现公司持续、健康和快速发展，秉承“恪守承诺、奉献健康”的企业宗旨，不断提升公司价值，实现投资者利益和客户价值最大化。

Sannuo biosensor Co., Ltd. is mainly engaged in the research, development, production and sales of real-time detection products by using biosensor technology, which is listed on the Shenzhen Stock Exchange. The stock is referred to as "sannuo biology" for short, with the stock code of 300298. The company's main products are micro blood fast blood glucose tester and matching blood glucose test strip, which constitute a blood glucose monitoring system for blood glucose monitoring. Sannuo biology was supported by the national innovation fund in 2003 and 2008, and is the undertaker of the national high-tech industrialization demonstration project of biomedical engineering. As one of the most important manufacturers of blood glucose monitoring system products in China, the "sxt-1", "safe and stable", "safe and accurate" blood glucose tester and supporting test strips produced by the company have obtained the registration certificate of medical device products, and the company has obtained the medical device production license after passing the on-site audit of Hunan food and drug administration. In addition, the company also passed the ISO: 13485 quality management system certification. In terms of product export, the company's blood glucose monitoring system products have passed the EU CE certification. The rapid growth of the company's performance depends on its unique profit model. The company's main products include blood glucose tester and matching test strips, which must be used in pairs. The company adopts the profit model of instrument occupying the market and consumables earning profits. It takes the market by providing affordable blood glucose meters and test strips for ordinary people. After the instrument is sold, it drives the corresponding test strips to show cumulative growth. In the past three years, the sales volume of instruments has increased significantly, with a compound growth rate of revenue of 25%; the price of test strip has remained stable, with a compound growth rate of revenue of 119% in the past three years. The establishment of "biosensor production base" will effectively consolidate and improve the company's comprehensive competitiveness in micro blood fast blood glucose tester and supporting blood glucose test strip products, improve the production process, improve the company's product quality, solve the problem of insufficient production capacity, and comprehensively enhance the company's competitive position in the domestic blood glucose monitoring system industry. It is helpful for the company to consolidate the domestic market, expand the international market, expand the market share, enhance the brand value, develop new products and further improve the core competitiveness. The "marketing network construction" project can further improve the company's product market coverage, enhance the product brand image, strengthen the company's customer service ability, and lay the foundation for the company to obtain a larger market share and cover a higher level market. Sannuo biology has established the largest and most professional marketing team in the domestic blood glucose testing industry. They are widely active in the markets at all levels, such as provinces, cities and counties across the country. They carry out a variety of promotional activities and patient education activities in a planned way, which promotes the rapid and large-scale shipment of sannuo series blood glucose meters, thus driving the continuous and rapid growth of the sales of blood glucose test strips matched with them, A large number of distributors and pharmacies that have cooperated for many years have also obtained considerable sales returns. Recently, the Ministry of science and technology announced the 12th Five Year Plan for the development of medical science and technology, which proposed to develop strategic emerging industries of biomedicine with the modernization of major new drugs, medical devices and traditional Chinese medicine as the core. The enterprises of blood glucose meter based on biosensor technology will benefit from the expansion of product market supported by policies. It is estimated that in the next five years, the market capacity of new blood glucose testers in China will be 4.682 billion yuan, and the annual consumption capacity of test strips will be 8.163 billion yuan, totaling 12.845 billion yuan. The huge market capacity will provide a strong guarantee for the rapid development of sannuobi. In the future, sannuobi will continue to be committed to the R & D and industrialization of POCT (real-time detection) products, and maintain the company's leading position in the blood glucose monitoring system industry, To lead the scale and marketization of POCT products for diabetes, cardiovascular diseases and infectious diseases, provide detection tools and information management services for emergency, bedside rapid detection and chronic disease management, form an Internet of things interactive system for disease management for monitoring, evaluation and intervention, and realize the sustainable, healthy and rapid development of the company. Adhering to the enterprise tenet of "abiding by the promise and contributing to health", we do not The company's value should be improved to maximize the interests of investors and customer value.

本文链接： https://brand.waitui.com/c122dddab.html 联系电话：0731-89935507